Switch theme
Sign up to access all valuation multiples
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
2019
41
Last FY Revenue n/a
LTM EBITDA -$84.5M
$343M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sionna Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$84.5M.
In the most recent fiscal year, Sionna Therapeutics achieved revenue of n/a and an EBITDA of -$69.9M.
Sionna Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sionna Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$84.5M | XXX | -$69.9M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$83.6M | XXX | -$70.6M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$74.1M | XXX | -$61.7M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sionna Therapeutics's stock price is $14.
Sionna Therapeutics has current market cap of $604M, and EV of $343M.
See Sionna Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $343M | $604M | XXX | XXX | XXX | XXX | $-10.47 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sionna Therapeutics has market cap of $604M and EV of $343M.
Sionna Therapeutics's trades at n/a EV/Revenue multiple, and -4.9x EV/EBITDA.
Equity research analysts estimate Sionna Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sionna Therapeutics has a P/E ratio of -8.1x.
See valuation multiples for Sionna Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $604M | XXX | $604M | XXX | XXX | XXX |
| EV (current) | $343M | XXX | $343M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -4.1x | XXX | -4.9x | XXX | XXX | XXX |
| EV/EBIT | -4.1x | XXX | -4.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -8.1x | XXX | -9.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -6.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSionna Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.7M for the same period.
Sionna Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sionna Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sionna Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 42% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sionna Therapeutics acquired XXX companies to date.
Last acquisition by Sionna Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Sionna Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sionna Therapeutics founded? | Sionna Therapeutics was founded in 2019. |
| Where is Sionna Therapeutics headquartered? | Sionna Therapeutics is headquartered in United States of America. |
| How many employees does Sionna Therapeutics have? | As of today, Sionna Therapeutics has 41 employees. |
| Who is the CEO of Sionna Therapeutics? | Sionna Therapeutics's CEO is Mr. Michael Cloonan. |
| Is Sionna Therapeutics publicy listed? | Yes, Sionna Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Sionna Therapeutics? | Sionna Therapeutics trades under SION ticker. |
| When did Sionna Therapeutics go public? | Sionna Therapeutics went public in 2025. |
| Who are competitors of Sionna Therapeutics? | Similar companies to Sionna Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Sionna Therapeutics? | Sionna Therapeutics's current market cap is $604M |
| Is Sionna Therapeutics profitable? | Yes, Sionna Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sionna Therapeutics? | Sionna Therapeutics's last 12 months EBITDA is -$84.5M. |
| What is the current EV/EBITDA multiple of Sionna Therapeutics? | Current EBITDA multiple of Sionna Therapeutics is -4.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
